Approval · Notice of Compliance 1706 · 2001
CO BROMOCRIPTINE: Notice of Compliance 1706
Issued October 12, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1706
- Date
- October 12, 2001
- Company
- Cobalt Pharmaceuticals IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- New product and manufacturer name
- Therapeutic class
- Prolactin inhibitor, growth hormone suppressant in acromegaly, adjunctive medication in parkinson's disease
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CO BROMOCRIPTINE | 02244640 | Cancelled Pre Market |
| CO BROMOCRIPTINE | 02244639 | Cancelled Pre Market |
Medicinal ingredients
- BROMOCRIPTINE MESYLATE 2.5 MG per TAB
- BROMOCRIPTINE MESYLATE 5 MG per CAP